[1]
Eggermont AM, Kirkwood JM. Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 2004; 40: 1825-36.
[2]
Ascierto PA, Kirkwood JM, Grob JJ, et al. The role of BRAF V600 mutation in melanoma. J Transl Med 2012; 10: 85.
[3]
Dummer R, Hauschild A, Lindenblatt N, Pentheroudakis G, Keilholz U. Cutaneous melanoma: ESMO clinical practice guidelines. Ann Oncol 2015; 26(Suppl. 5): V126-32.
[4]
Raaijmakers MI, Rozati S, Goldinger SM. Melanoma immunotherapy: Historical precedents, recent successes and future prospects. Immunotherapy 2013; 5(2): 169-82.
[5]
Atkins MB, Kunkel L, Sznol M, et al. High-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: Long-term survival update. Cancer J 2000; 6(Suppl. 1): S11-4.
[6]
Mocellin S, Lens MB, Pasquali S, Pilati P. Interferon alpha for the adjuvant treatment of cutaneous melanoma. Cochrane Database Syst Rev 2013; 18(6)CD008955
[7]
Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363(8): 711-23.
[8]
Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J 1992; 11: 3887-95.
[9]
Riley JL. PD-1 signaling in primary T cells. Immunol Rev 2009; 229: 114-25.
[10]
Dai S, Jia R, Zhang X, et al. The PD-1/PD-Ls pathway and autoimmune diseases. Cell Immunol 2014; 290(1): 72-9.
[11]
Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer 2012; 12: 252-64.
[12]
Dyck L, Wilk MM, Raverdeau M. Anti-PD-1 inhibits Foxp3+ Treg cell conversion and unleashes intratumoural effector T cells thereby enhancing the efficacy of a cancer vaccine in a mouse model. Cancer Immunol Immunother 2016; 65(12): 1491-8.
[13]
Fry AM, Lanier LL, Weiss A. Phosphotyrosines in the killer cell inhibitory receptor motif of NKB1 are required for negative signaling and for association with protein tyrosine phosphatase 1C. J Exp Med 1996; 184: 295-300.
[14]
Lorenz U. SHP-1 and SHP-2 in T cells: Two phosphatases functioning at many levels. Immunol Rev 2009; 228: 342-59.
[15]
Muenst S, Soyal SD, Tzankov A, Hoeller S. The PD-1/PD-L1 pathway: biological background and clinical relevance of an emerging treatment target in immunotherapy. Expert Opin Ther Targets 2015; 19(2): 201-11.
[16]
Li J, Jie HB, Lei Y, Gildener-Leapman N, Trivedi S, Green T. PD-1/SHP-2 inhibits Tc1/Th1 phenotypic responses and the activation of T cells in the tumor microenvironment. Cancer Res 2015; 75(3): 508-18.
[17]
Okazaki T, Honjo T. The PD-1-PD-L pathway in immunological tolerance. Trends Immunol 2006; 27: 195-201.
[18]
Ishiwata K, Watanabe N, Guo M, et al. Costimulator B7-DC attenuates strong Th2 responses induced by Nippostrongylus brasiliensis. J Immunol 2010; 184(4): 2086-94.
[19]
Sznol M, Chen LP. Antagonist antibodies to PD-1 and B7-H1 (PD-L1) in the treatment of advanced human cancer. Clin Cancer Res 2013; 19(5): 1021-34.
[20]
Butte MJ, Keir ME, Phamduy TB, et al. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 2007; 27(1): 111-22.
[21]
Weber Jeffrey S. Minor D, et al.Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): A randomised, controlled, open-label, phase 3 trial. Lancet Oncol 2015; 16(4): 375-84.
[22]
Robert C, Long GV, Brady B, Dutriaux C. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320-30.
[23]
Larkin J, Chiarion-Sileni V, Gonzalez R. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23-34.
[24]
Robert C, Schachter J, Long GV. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521-32.
[25]
Genentech, Inc. A phase 1b study of atezolizumab in combination
with vemurafenib or vemurafenib plus cobimetinib in participants
with BRAFV600-mutation positive metastatic melanoma. Clinical-
Trials.gov Identifier: NCT01656642, 2012.
[26]
Hodi FS, Kluger HM, Sullivan RJ, et al. Clinical activity of the PD-L1 inhibitor MPDL3280A in patients with metastatic melanoma: Updated phase I data. In Society for Melanoma Research 2014 Congress. Pigment Cell Melanoma Res 2014; 27: 1169-98.
[27]
Genentech, Inc. Phase 1 Safety and tolerability of MEDI4736 in
combination with dabrafenib and trametinib or with trametinib
alone. ClinicalTrials.gov Identifier: NCT02027961, 2014.
[28]
Genentech, Inc. A study of epacadostat (INCB024360) in combination
with durvalumab (MEDI4736) in subjects with selected advanced
solid tumors (ECHO-203) ClinicalTrials.gov Identifier:
NCT02318277, 2014.
[29]
Riella LV, Paterson AM. Role of the PD-1 pathway in the immune response. Am J Transplant 2012; 12(10): 2575-87.
[30]
Taube JM, Anders RA, Young GD, et al. Colocalization of inflammatory response with B7-h1 expression in human melanocytic lesions supports an adaptive resistance mechanism of immune escape. Sci Transl Med 2012; 4127ra37
[31]
Spranger S. Mechanisms of tumor escape in the context of the T-cell-inflamed and the non-T-cell-inflamed tumor microenvironment. Int Immunol 2016; 28(8): 383-91.
[32]
Chen DS, Mellman I. Oncology meets immunology: The cancer-immunity cycle. Immunity 2013; 39: 1-10.
[33]
Corrales L, Glickman LH, McWhirter SM, et al. Direct activation of STING in the tumor microenvironment leads to potent and systemic tumor regression and immunity. Cell Rep 2015; 11: 1018.
[34]
Martinez-Lostao L, Anel A, Pardo J. How do cytotoxic lymphocytes kill cancer cells? Clin Cancer Res 2015; 21: 5047-56.
[35]
Galon J, Mlecnik B, Bindea G, et al. Towards the introduction of the ‘Immunoscore’ in the classification of malignant tumours. J Pathol 2014; 232(2): 199-209.
[36]
Spranger S, Spaapen RM, Zha Y, et al. Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells. Sci Transl Med 2013; 5200ra116
[37]
Hwang SL, Chung NP, Chan JK, Lin CL. Indoleamine 2,3-dioxygenase (IDO) is essential for dendritic cell activation and chemotactic responsiveness to chemokines. Cell Res 2005; 15: 167-75.
[38]
Soliman H. Indoleamine 2,3-dioxygenase: Is it an immune suppressor? Cancer J 2010; 16(4): 354-9.
[39]
Pandiyan P, Zheng L, Ishihara S, Reed J, Lenardo MJ. CD4+CD25+Foxp3+ regulatory T cells induce cytokine deprivation-mediated apoptosis of effector CD4+ T cells. Nat Immunol 2007; 8: 1353.
[40]
Read S, Greenwald R, Izcue A, et al. Blockade of CTLA-4 on CD4+CD25+ regulatory T cells abrogates their function in vivo. J Immunol 2006; 177: 4376.
[41]
Klages K, Mayer CT, Lahl K, et al. Selective depletion of Foxp3+ regulatory T cells improves effective therapeutic vaccination against established melanoma. Cancer Res 2010; 70: 7788-99.
[42]
Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance and tumor immune escape. J Cell Physiol 2003; 195(3): 346-55.
[43]
Johnston RJ, Comps-Agrar L, Hackney J, et al. The immunoreceptor TIGIT regulates antitumor and antiviral CD8(+) T cell effector function. Cancer Cell 2014; 26: 923-37.
[44]
Kim JM, Chen DS. Immune escape to PD-L1/PD-1 blockade: Seven steps to success (or failure). Ann Oncol 2016; 27: 1492-504.
[45]
Snyder A, Makarov V, Merghoub T, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med 2014; 371: 2189-99.
[46]
Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol 2004; 22: 329-60.
[47]
Chen L, Flies DB. Molecular mechanisms of T cell co-stimulation and coinhibition. Nat Rev Immunol 2013; 13: 227-42.
[48]
Shindo Y, Yoshimura K, Kuramasu A, et al. Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor. Anticancer Res 2015; 35: 129-36.
[49]
Guo Z, Wang X, Cheng D, et al. PD-1 blockade and OX40 triggering synergistically protects against tumor growth in a murine model of ovarian cancer. PLoS One 2014; 9e89350
[50]
Mikucki ME, Fisher DT, Matsuzaki J, et al. Non-redundant requirement for CXCR3 signalling during tumoricidal T-cell trafficking across tumour vascular checkpoints. Nat Commun 2015; 6: 7458.
[51]
Proost P, Mortier A, Loos T, et al. Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. Blood 2007; 110: 37-44.
[52]
Curran MA, Montalvo W, Yagita H, Allison JP. PD-1 and CTLA-4 combination blockade expands infiltrating T cells and reduces regulatory T and myeloid cells within B16 melanoma tumors. Proc Natl Acad Sci USA 2010; 107: 4275-80.
[53]
Parry RV, et al. CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms. Mol Cell Biol 2005; 25: 9543-53.
[54]
Egen JG, Kuhns MS, Allison JP. CTLA-4: New insights into its biological function and use in tumor immunotherapy. Nat Immunol 2002; 3: 611-8.
[55]
Collins AV, Brodie DW, Gilbert RJ, et al. The interaction properties of costimulatory molecules revisited. Immunity 2002; 17: 201-10.
[56]
Walker LS, Sansom DM. The emerging role of CTLA-4 as a cell-extrinsic regulator of T cell responses. Nat Rev Immunol 2011; 11: 852-63.
[57]
Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122-33.
[58]
Hodi FS, Chesney J, Pavlick AC, et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2-year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 2016; 17(11): 1558-68.
[59]
Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med 2014; 371: 1867-76.
[60]
Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med 2015; 372: 30-9.
[61]
Bartkowiak T, Curran MA. 4-1BB agonists: Multi-potent potentiators of tumor immunity. Front Oncol 2015; 5: 117.
[62]
Wang C, Lin GH, McPherson AJ, Watts TH. Immune regulation by 4-1BB and 4-1BBL: Complexities and challenges. Immunol Rev 2009; 229(1): 192-215.
[63]
Ju SA, Lee SC, Kwon TH. Immunity to melanoma mediated by 4-1BB is associated with enhanced activity of tumour-infiltrating lymphocytes. Immunol Cell Biol 2005; 83(4): 344-51.
[64]
Squibb BM. Study of BMS-663513 in Patients with advanced
cancer. ClinicalTrials.gov Identifier: NCT00309023, 2006.
[65]
Squibb BM. Phase II, 2nd Line Melanoma - RAND Monotherapy.
ClinicalTrials.gov Identifier: NCT00612664 2008.
[66]
Squibb BM. Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma. ClinicalTrialsgov Identifier: NCT00803374, 2006.
[67]
Mahoney KM, Rennert PD, Freeman GJ. Combination cancer immunotherapy and new immunomodulatory targets. Nat Rev Drug Discov 2015; 14(8): 561-84.
[68]
Schaer DA, Hirschhorn-Cymerman D, Wolchok JD. Targeting tumor-necrosis factor receptor pathways for tumor immunotherapy. J Immunother Cancer 2014; 2: 7.
[69]
Medlmmune LCC. A phase 1b/2 safety and tolerability of
MEDI6469 in combination with therapeutic immune agents or
monoclonal antibodies (MEDI6469). ClinicalTrials.gov Identifier:
NCT02205333 2013.
[70]
Triebel F, Jitsukawa S, Baixeras E, Roman-Roman S. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med 1990; 171(5): 1393-405.
[71]
Huard B, Gaulard P, Faure F, Hercend T, Triebel F. Cellular expression and tissue distribution of the human LAG-3-encoded protein, an MHC class II ligand. Immunogenetics 1994; 39(3): 213-7.
[72]
Maçon-Lemaître L, Triebel F. The negative regulatory function of the lymphocyte-activation gene-3 co-receptor (CD223) on human T cells. Immunology 2005; 115(2): 170-8.
[73]
Woo SR, Turnis ME, Goldberg MV. Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T cell function to promote tumoral immune escape. Cancer Res 2012; 72(4): 917-27.
[74]
Squibb BM. Safety study of anti-LAG-3 with and without anti-PD-1 in the treatment of solid tumors. ClinicalTrialsgov Identifier:
NCT01968109, 2013.
[75]
Yu X, Harden K, Gonzalez LC, Francesco M, Chiang E, Irving B. The surface protein TIGIT suppresses T cell activation by promoting the generation of mature immunoregulatory dendritic cells. Nat Immunol 2009; 10(1): 48-57.
[76]
Li M, Xia P, Du Y, et al. T-cell immunoglobulin and ITIM domain (TIGIT) receptor/poliovirus receptor (PVR) ligand engagement suppresses interferon-gamma production of natural killer cells via β-arrestin 2-mediated negative signaling. J Biol Chem 2014; 289: 17647-57.
[77]
Chauvin JM, Pagliano O, Fourcade J, et al. TIGIT and PD-1 impair tumor antigen-specific CD8(+) T cells in melanoma patients. J Clin Invest 2015; 125(5): 2046-58.
[78]
McIntire JJ, Umetsu SE, Akbari O, et al. Identification of Tapr (an airway hyperreactivity regulatory locus) and the linked Tim gene family. Nat Immunol 2001; 2: 1109-16.
[79]
Monney L, Sabatos CA, Gaglia JL, et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002; 415: 536-41.
[80]
Anderson AC. Tim-3: An emerging target in the cancer immunotherapy landscape. Cancer Immunol Res 2014; 2(5): 393-8.
[81]
Zhu C, Anderson AC, Schubart A, et al. The Tim-3 ligand galectin-9 negatively regulates T helper type 1 immunity. Nat Immunol 2005; 6: 1245-52.
[82]
Fourcade J, Sun Z, Benallaoua M, et al. Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+T cell dysfunction in melanoma patients. J Exp Med 2010; 207: 2175-86.
[83]
Sakuishi K, Apetoh L, Sullivan JM, et al. Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity. J Exp Med 2010; 207: 2187-94.
[84]
Tesaro. A phase 1 study of TSR-022, an anti-TIM-3 monoclonal
antibody, in patients with advanced solid tumors. ClinicalTrials.gov
Identifier: NCT02817633, 2106.
[85]
Novartics Pharmaceuticals. Safety and efficacy of MBG453 as
single agent and in combination with PDR001 in patients with advanced
malignancies. ClinicalTrials.gov Identifier: NCT02608268 2015.
[86]
Munn DH. Blocking IDO activity to enhance antitumor immunity. Front Biosci (Elite Ed) 2012; 4: 734-45.
[87]
Beatty GL, O’Dwyer PJ, Clark J, et al. Phase I study of the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of the oral inhibitor of indoleamine 2,3-dioxygenase (IDO1) INCB024360 in patients (pts) with advanced malignancies. J Clin Oncol 2013; 31: 3025.
[88]
Fred Hutchinson Cancer Research Center.Epacadostat and vaccine therapy in treating patients with stage IIIIV melanoma.ClinicalTrials.
gov Identifier: NCT01961115 2013.
[89]
Incyte Corporation. A phase 1/2 randomized, blinded, placebo
controlled study of ipilimumab in combination with INCB024360
or placebo in subjects with unresectable or metastatic melanoma.
ClinicalTrials.gov Identifier: NCT01604889, 2012.
[90]
Merck Sharp & Dohme Corp. Study of INCB024360 alone and in
combination with pembrolizumab (MK-3475) in solid tumors
(MK-3475-434) (KEYNOTE-434) ClinicalTrials.gov Identifier:
NCT02862457, 2016.
[91]
Straume O, Akslen LA. Expresson of vascular endothelial growth factor, its receptors (FLT-1, KDR) and TSP-1 related to microvessel density and patient outcome in vertical growth phase melanomas. Am J Pathol 2001; 159(1): 223-35.
[92]
Schuster C, Eikesdal HP, Puntervoll H, et al. Clinical efficacy and safety of bevacizumab monotherapy in patients with metastatic melanoma: Predictive importance of induced early hypertension. PLoS One 2012; 7(6)e38364
[93]
Kim KB, Sosman JA, Fruehauf JP, et al. BEAM: A randomized phase II study evaluating the activity of bevacizumab in combination with carboplatin plus paclitaxel in patients with previously untreated advanced melanoma. J Clin Oncol 2012; 30(1): 34-41.
[94]
Kottschade LA, Suman VJ, Perez DG, et al. A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin and bevacizumab in patients with unresectable stage IV melanoma: A North Central Cancer Treatment Group study, N0775. Cancer 2013; 119(3): 586-92.
[95]
Mansfield AS, Nevala WK, Lieser EA, Leontovich AA, Markovic SN. The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma. OncoImmunology 2013; 2e24436
[96]
Hodi FS, Lawrence D, Lezcano C, Wu X, Zhou J, Sasada T. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol Res 2014; 2(7): 632-42.
[97]
Ipilimumab with or without bevacizumab in treating patients with
stage III-IV melanoma that cannot be removed by surgery. ClinicalTrials.
gov Identifier: NCT01950390
[98]
Ott PA, Hodi FS, Buchbinder EI. Inhibition of immune checkpoints and vascular endothelial growth factor as combination therapy for metastatic melanoma: An overview of rationale, preclinical evidence, and initial clinical data. Front Oncol 2015; 5: 202.
[99]
McCubrey JA, Steelman LS, Chappell WH, et al. Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta 2007; 1773(8): 1263-84.
[100]
Stewart R, Poon E, Mullins S, Watkins A. Immune mediated therapy and MEK inhibition: preclinical assessment of immunobiology and combination activity in vitro and in vivo. J Immunother Cancer 2014; 2(Suppl. 3): 128.
[101]
Irving BA, Cheung J, Yang Y, Moskalenka M. MAP kinase inhibitors stimulate T cell and anti-tumor activity in combination with blockade of the PD-L1/PD-1 interaction. J Immunother Cancer 2013; 1(Suppl. 1): 79.
[102]
Hoffmann-La Roche. Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors.ClinicalTrials.gov Identifier: NCT01988896, 2013.
[103]
Hoffmann-La Roche.A study of atezolizumab plus cobimetinib and vemurafenib versus placebo plus cobimetinib and vemurafenib in previously untreated BRAFV600 mutation-positive participants with metastatic or unresectable locally advanced melanoma.ClinicalTrials.
gov Identifier: NCT02908672, 2016.
[104]
Hoffmann-La Roche A study to investigate efficacy and safety of cobimetinib plus atezolizumab and atezolizumab monotherapy versus regorafenib in participants with metastatic colorectal adenocarcinoma.ClinicalTrials.gov Identifier: NCT02788279, 2016.
[105]
Hoffmann-La Roche. A study of the safety and efficacy of pembrolizumab
(mk-3475) in combination with trametinib and dabrafenib
in participants with advanced melanoma (MK-3475-
022/KEYNOTE-022). ClinicalTrials.gov Identifier: NCT02130466 2016.